Minerva Neurosciences, Inc.
NASDAQ:NERVBiotechnology
-$0.30 today
- Market cap
- $108.64M
- Beta
- -0.11
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$8.46
Volume 0.28M
Average 0.21M
NERV Operating Cash Flow
Cash generated by the company's core business operations during the period.
Minerva Neurosciences, Inc.NASDAQ: NERV
Operating Cash Flow · Q2 FY2026 · quarter ended Jun 2026
Operating cash flow grows 653373.0% year over year
Q2 FY2026 operating cash flow of $13.34B (cash outflow) rose 653373.0% year over year. Sequentially, it rose 145.9% from the prior quarter. Over 3 fiscal years it compounded at +718.4% a year.
Context
- Operating cash flow grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (13.51B) USD
- Year-over-year change
- -69007.6%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (13.51B) | -69007.6% |
| FY2024 | 2024-12-31 | (19.55M) | -32.2% |
| FY2023 | 2023-12-31 | (14.78M) | +40.0% |
| FY2022 | 2022-12-31 | (24.65M) | -0.2% |
| FY2021 | 2021-12-31 | (24.6M) | — |
Operating Cash Flow vs competitors
How NERV compares with its peers on the latest reported figures
- NERV's LTM Jun 2026 operating cash flow of $18.78B is the largest of the 4 companies compared; the peer median is $10.69M.
- Over three fiscal years its annual growth of +718.4% compares with a peer median of -19.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $18.78B | — | +718.4% | — | |
| LTM Mar 2026 | $27.59M | -37.3% | -19.6% | 3215.2% | |
| LTM Dec 2025 | $10.69M | -17.8% | -24.2% | — | |
NRXSNeurAxis, Inc. | LTM Mar 2026 | $6.06M | -4.9% | +40.9% | 141.5% |
| Peer median (excluding NERV) | $10.69M | -17.8% | -19.6% | 1678.3% | |
Competitors are the stored peer set for NERV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (49.91M) | (32.11M) | (30.01M) | 1.44M | (293.42M) |
| Depreciation & Amortization | 101.79K | 8.51K | 30.98K | 22.47K | 5.44M |
| Deferred Income Tax | (1.8M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 5.22M | 4.11M | 1.97M | 1.33M | 1.33B |
| Change in Working Capital | 259.34K | (4.06M) | 4.94M | (320.6K) | (632.35K) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 857.6K | (883.55K) | 835.65K | (197.48K) | (1.06M) |
| Other Working Capital | (598.27K) | (3.18M) | 4.1M | (123.13K) | 426.67K |
| Other Non-Cash Items | 21.53M | 7.41M | 8.28M | (22.02M) | (14.55B) |
| Operating Cash Flow | (24.6M) | (24.65M) | (14.78M) | (19.55M) | (13.51B) |
| Capital Expenditures | 0 | (16.33K) | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | (16.33K) | 0 | 0 | 0 |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 0 | 20M | 0 | 74.45M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 60M | (5) | (396.29K) | 0 | 74.38B |
| Financing Cash Flow | 60M | (5) | 19.6M | 0 | 74.45B |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 35.4M | (24.66M) | 4.82M | (19.55M) | 60.94B |
| Free Cash Flow | (24.6M) | (24.66M) | (14.78M) | (19.55M) | (13.51B) |
Minerva Neurosciences, Inc.
NASDAQ:NERV
Intrinsic Alpha fair value
Locked
Current Price
$2.18
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.